Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

Market Cap	7.71B +38.5%
Revenue (ttm)	1.29B +8.4%
Net Income	-308.33M
EPS	-0.15
Shares Out	2.06B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,424,098
Average Volume	123,132,776
Open	4.040
Previous Close	3.650
Day's Range	3.670 - 4.040
52-Week Range	2.140 - 4.830
Beta	0.30
RSI	44.35
Earnings Date	Apr 23, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,453
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300267

Financial Performance

In 2024, SHE:300267's revenue was 1.14 billion, a decrease of -36.09% compared to the previous year's 1.78 billion. Losses were -373.37 million, 91.2% more than in 2023.